Jiří Tomášek
About
Jiří Tomášek is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology.
According to data from OpenAlex, Jiří Tomášek has authored 61 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 15 papers in Epidemiology. Recurrent topics in Jiří Tomášek's work include Gastric Cancer Management and Outcomes (20 papers), Colorectal Cancer Treatments and Studies (20 papers) and Neuroendocrine Tumor Research Advances (9 papers). Jiří Tomášek is often cited by papers focused on Gastric Cancer Management and Outcomes (20 papers), Colorectal Cancer Treatments and Studies (20 papers) and Neuroendocrine Tumor Research Advances (9 papers). Jiří Tomášek collaborates with scholars based in Czechia, United States and Italy. Jiří Tomášek's co-authors include Bohuslav Melichar, Jakub Żołnierek, Thomas E. Hutson, Begoña Mellado, James Larkin, Hanjoo Kim, Karen Wood, Pablo Maroto, M. Dror Michaelson and Corina E. Dutcus and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
In The Last Decade
Jiří Tomášek
52 papers receiving 1.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jiří Tomášek Czechia | 16 | 834 | 680 | 524 | 418 | 187 | 61 | 1.4k | ||
| Olivier Dubreuil France | 15 | 498 0.6× | 932 1.4× | 310 0.6× | 382 0.9× | 378 2.0× | 56 | 1.6k | ||
| Jan Cosaert United States | 17 | 644 0.8× | 1.1k 1.5× | 438 0.8× | 336 0.8× | 128 0.7× | 43 | 1.5k | ||
| Atsushi Horiike Japan | 28 | 1.3k 1.6× | 1.3k 1.9× | 604 1.2× | 391 0.9× | 127 0.7× | 107 | 2.1k | ||
| Natsuko Okita Japan | 20 | 518 0.6× | 855 1.3× | 278 0.5× | 135 0.3× | 271 1.4× | 110 | 1.3k | ||
| Walter L. Vervenne Netherlands | 14 | 729 0.9× | 1.3k 1.8× | 530 1.0× | 561 1.3× | 322 1.7× | 35 | 1.8k | ||
| Sibyl Anderson United States | 19 | 1.2k 1.5× | 695 1.0× | 944 1.8× | 524 1.3× | 218 1.2× | 40 | 2.1k | ||
| Beata Korytowsky United States | 17 | 617 0.7× | 565 0.8× | 370 0.7× | 250 0.6× | 78 0.4× | 78 | 1.1k | ||
| Yu-Nien Sun United States | 10 | 332 0.4× | 566 0.8× | 528 1.0× | 196 0.5× | 122 0.7× | 12 | 1.4k | ||
| Tae-You Kim South Korea | 24 | 420 0.5× | 689 1.0× | 678 1.3× | 277 0.7× | 168 0.9× | 48 | 1.5k | ||
| N. Schleucher Germany | 19 | 610 0.7× | 802 1.2× | 598 1.1× | 186 0.4× | 359 1.9× | 32 | 1.6k |
Countries citing papers authored by Jiří Tomášek
Since
Specialization
Citations
This map shows the geographic impact of Jiří Tomášek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiří Tomášek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiří Tomášek more than expected).
Fields of papers citing papers by Jiří Tomášek
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jiří Tomášek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiří Tomášek. The network helps show where Jiří Tomášek may publish in the future.
Co-authorship network of co-authors of Jiří Tomášek
This figure shows the co-authorship network connecting the top 25 collaborators of Jiří Tomášek. A scholar is included among the top collaborators of Jiří Tomášek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiří Tomášek. Jiří Tomášek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sobrero, Alberto, Sara Lonardi, Rocio García‐Carbonero, et al.. (2023). Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.. Journal of Clinical Oncology. 41(4_suppl). 67–67.
2.
Shah, Manish A., Takayuki Yoshino, Niall C. Tebbutt, et al.. (2022). Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. Clinical Colorectal Cancer. 22(1). 100–110.
3.
Galle, Peter R., Masatoshi Kudo, Josep M. Llovet, et al.. (2020). Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2. Journal of Hepatology. 73. S386–S387.
4.
Fazio, Nicola, Jean-François Martini, Adina Croitoru, et al.. (2019). Pharmacogenomic Analyses of Sunitinib In Patients With Pancreatic Neuroendocrine Tumors. Future Oncology. 15(17). 1997–2007.
5.
Kudo, Masatoshi, Peter R. Galle, Kenta Motomura, et al.. (2019). Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2). Annals of Oncology. 30. v292–v292.
6.
Cutsem, Eric Van, Takayuki Yoshino, Heinz‐Josef Lenz, et al.. (2018). Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Annals of Oncology. 29(9). 1955–1963.
7.
Tabernero, Josep, Atsushi Ohtsu, Kei Muro, et al.. (2017). Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics. 16(10). 2215–2222.
8.
Krieken, J. Han van, George Kafatos, James A. Bennett, et al.. (2017). Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review. BMC Cancer. 17(1). 798–798.
9.
Singh, Simron, Carlo Carnaghi, Roberto Buzzoni, et al.. (2017). Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 106(3). 211–220.
10.
Cutsem, Eric Van, Takayuki Yoshino, Heinz‐Josef Lenz, et al.. (2016). gastrointestinal tumours, colorectal Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study. Annals of Oncology. 27. vi559–vi559.
11.
Kopečková, Kateřina, Tomáš Büchler, Zbyněk Bortlíček, et al.. (2016). Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. Targeted Oncology. 12(1). 89–95.
12.
Fuchs, Charles S., Josep Tabernero, Jiří Tomášek, et al.. (2016). Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. British Journal of Cancer. 115(8). 974–982.
13.
Motzer, Robert J., Thomas E. Hutson, Hilary Glen, et al.. (2015). Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. The Lancet Oncology. 16(15). 1473–1482.
14.
Fuchs, Charles S., Josep Tabernero, Jiří Tomášek, et al.. (2015). Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).. Journal of Clinical Oncology. 33(15_suppl). 4029–4029.
15.
Halámková, Jana, Zdeněk Pavlovský, Jiří Tomášek, et al.. (2012). Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients. Neoplasma. 60(2). 151–159.
16.
Halámková, Jana, et al.. (2011). [Plasminogen activator system and its clinical significance in patients with a malignant disease].. PubMed. 24(6). 418–23.
17.
Halámková, Jana, Zdeněk Pavlovský, Jiří Tomášek, et al.. (2011). Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients. Neoplasma. 58(5). 377–385.
18.
Hermanová, Markéta, Petr Karásek, Rudolf Nenutil, et al.. (2009). Clinicopathological Correlations of Cyclooxygenase-2, MDM2, and p53 Expressions in Surgically Resectable Pancreatic Invasive Ductal Adenocarcinoma. Pancreas. 38(5). 565–571.
19.
Válek, Vlastimil, et al.. (2007). Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: A prospective randomised study. European Journal of Radiology. 62(2). 175–179.
20.
Žaloudík, Jan, Rostislav Vyzula, Jiří Tomášek, et al.. (2001). [In vitro testing for drug resistance and drug sensitivity in clinical oncology].. PubMed. 47(9). 621–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Olivier Dubreuil Breakdown of academic impact, for papers by Jan Cosaert Breakdown of academic impact, for papers by Atsushi Horiike Breakdown of academic impact, for papers by Natsuko Okita Breakdown of academic impact, for papers by Walter L. Vervenne Breakdown of academic impact, for papers by Sibyl Anderson Breakdown of academic impact, for papers by Beata Korytowsky Breakdown of academic impact, for papers by Yu-Nien Sun Breakdown of academic impact, for papers by Tae-You Kim Breakdown of academic impact, for papers by N. Schleucher